Skip to main content

ACNS0332 ACNS0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients

NCT00392327

ACNS0332: Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-Apoptotic Agent in other than Average Risk Medulloblastoma/PNET Patients

Associated Conditions

Brain Cancer

Principal Investigator

Sponsor

Children's Oncology Group

The overall goal of this study is to compare the effects, good and/or bad, of the chemotherapy drugs carboplatin and isotretinoin on subjects with high risk medulloblastoma and to find out if one or both are better than standard therapy alone. In this study you will get either standard therapy alone, standard therapy plus one of the chemotherapy drugs added to the regimen, or standard therapy plus both of the chemotherapy drugs. The main aims of this study are: 1. To find out if giving the drug carboplatin along with radiation therapy is more effective than giving radiation therapy alone. 2. To find out if the drug isotretinoin can improve the survival of subjects with high risk medulloblastoma. Other aims of this study are: 3. To measure any effects that the different types of treatment have on the subjects quality of life (general well-being). 4. To measure the brain function of subjects (measuring intelligence, memory, language, nonverbal skills, attention, and academic achievement) and to examine the relationship between the subjects level of brain function and their quality of life. An additional research aim for which participation is optional is: 5. To identify markers in the DNA of tumor tissue that will help us know how best to treat patients in the future and to pick the most promising new therapies for future studies. All of the drugs used on this study are FDA approved for various kinds of cancers and commercially available, but using them together with radiation therapy in this way is experimental treatment.